BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32720048)

  • 21. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Deapen D; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2020 Apr; 6(4):e196400. PubMed ID: 32027353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The psychosocial impact of contralateral risk reducing mastectomy (CRRM) on women: A rapid review.
    Collins K; Gee M; Clack A; Wyld L
    Psychooncology; 2018 Jan; 27(1):43-52. PubMed ID: 28453892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.
    Yi M; Hunt KK; Arun BK; Bedrosian I; Barrera AG; Do KA; Kuerer HM; Babiera GV; Mittendorf EA; Ready K; Litton J; Meric-Bernstam F
    Cancer Prev Res (Phila); 2010 Aug; 3(8):1026-34. PubMed ID: 20647335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Moderate-Risk Breast Cancer Genes with Contralateral Prophylactic Mastectomy and Bilateral Disease.
    Zhang JQ; Dos Anjos CH; Sevilimedu V; Crown A; Amoroso KA; Pilewskie ML; Robson ME; Gemignani ML
    Ann Surg Oncol; 2023 Nov; 30(12):6990-6999. PubMed ID: 37661222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients.
    Falco G; Rocco N; Bordoni D; Marano L; Accurso A; Buccelli C; Di Lorenzo P; Capasso E; Policino F; Niola M; Ferrari G
    Open Med (Wars); 2016; 11(1):238-241. PubMed ID: 28352801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.
    Moukadem HA; Al Masry A; Atwani RW; Kreidieh F; Khalil LE; Saroufim R; Daouk S; Dalle IA; El Saghir NS
    Eur J Breast Health; 2022 Jan; 18(1):16-20. PubMed ID: 35059587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative genetic testing affects surgical decision making in breast cancer patients.
    Lokich E; Stuckey A; Raker C; Wilbur JS; Laprise J; Gass J
    Gynecol Oncol; 2014 Aug; 134(2):326-30. PubMed ID: 24910453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of large panel genetic evaluation of breast cancer patients in a community-based cancer institute.
    Bagwell AK; Sutton TL; Gardiner S; Johnson N
    Am J Surg; 2021 Jun; 221(6):1159-1163. PubMed ID: 33849710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England.
    Basu NN; Littlechild S; Barr L; Ross GL; Evans DG
    Ann R Coll Surg Engl; 2016 Feb; 98(2):121-7. PubMed ID: 26741657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
    Elsayegh N; Kuerer HM; Lin H; Gutierrez Barrera AM; Jackson M; Muse KI; Litton JK; Albarracin C; Afrough A; Hortobagyi GN; Arun BK
    Ann Surg Oncol; 2014 Oct; 21(11):3466-72. PubMed ID: 24796968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy.
    Murphy RX; Adkinson JM; Namey T; Eid S; Bleznak A
    Ann Plast Surg; 2010 May; 64(5):684-7. PubMed ID: 20395792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.